Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010
Authors:
- A. García FernándezAFA. García Fernández
- N. GiménezNGN. Giménez
- M. FraileMFM. Fraile
- S. GonzálezSGS. González
- C. ChabreraCCC. Chabrera
- M. TorrasMTM. Torras
- C. GonzálezCGC. González
- A. SalasASA. Salas
- I. BarcoIBI. Barco
- L. CireraLCL. Cirera
- M.J. CambraMCM.J. Cambra
- E. VelosoEVE. Veloso
Open Access
- 1 June 2012
- journal article
- Published by Elsevier in The Breast
- Vol. 21 (3) , 366-373
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Triple negative breast cancer: unmet medical needsBreast Cancer Research and Treatment, 2010
- Estrogen receptor-β expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health StudyLaboratory Investigation, 2009
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2009
- The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004Cancer, 2008
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001